Drug Trial Radar · NCT07920783
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
Jul 30, 2027
Study completion Nov 9, 2027
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a high-fat meal on the pharmacokinetics of GLR2053.
Conditions
- Atopic Dermatitis
Interventions
GLR2053 TabletsDrug
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of GLR2053.
PlaceboDrug
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of adverse events (AEs)Time frame: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
- The incidence of serious adverse events (SAEs)Time frame: SAD:Baseline to Day14 MAD:Baseline to Day38 FE:Baseline to Day12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.